SCHEMBL1010168

SCHEMBL1010168

CC(C)(C)OC(=O)N1CCC(O)(c2cc(F)cc(S(C)(=O)=O)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 19/20 0.48
S1PR2 O95136 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3387610 0.88 HDAC2 (0.43) GPR119
SCHEMBL22266048 0.83 HDAC2 (0.41) GPR119
SCHEMBL7534118 0.83 HDAC2 (0.43) GPR119
SCHEMBL3385458 0.82 MEN1 (0.43) S1PR2
SCHEMBL2427136 0.81 RORC (0.44) GPR119
SCHEMBL1010791 0.81 GPR119 (0.43) GPR119S1PR2
SCHEMBL14077925 0.79 S1PR2 (0.41) S1PR2
SCHEMBL4293214 0.79 OPRM1 (0.49) GPR119
SCHEMBL15804317 0.79 MEN1 (0.45) S1PR2
SCHEMBL1669692 0.78 GPR119 (0.42) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501777-B2 1-ethyl-4-[3-fluoro-5-(methylsulfonyl)phenyl]piperidine; central nervous system disorders, Parkinson's disease, Parkinsonism, dyskinesias, including L-DOPA induced dyskinesias, dystonias, tics, tremor, Huntington disease NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2013-08-06 US disclosed
US-8501777-B2 1-ethyl-4-[3-fluoro-5-(methylsulfonyl)phenyl]piperidine; central nervous system disorders, Parkinson's disease, Parkinsonism, dyskinesias, including L-DOPA induced dyskinesias, dystonias, tics, tremor, Huntington disease NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2013-08-06 US disclosed
EP-1948606-B1 3, 5-DISUBSTITUTED PHENYL-PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB AF NEUROSEARCH SWEDEN AB (DK) 2011-01-05 EP disclosed
US-20080234321-A1 3,5-Disubstituted Phenyl-Piperidines as Modulators of Dopamine Neurotransmission SANIONA AB (DK) 2008-09-25 US disclosed
US-20080234321-A1 3,5-Disubstituted Phenyl-Piperidines as Modulators of Dopamine Neurotransmission SANIONA AB (DK) 2008-09-25 US disclosed
WO-2007042295-A1 3, 5-DISUBSTITUTED PHENYL-PIPERIDINES AS MDULATORS OF DOPAMINE? NEUROTRANSMISSION NEUROSEARCH SWEDEN AB (SE) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234321-A1 3,5-Disubstituted Phenyl-Piperidines as Modulators of Dopamine Neurotransmission SLC6A3, DRD2, DRD3 GPR119 265/4885S1PR2 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.